Epidermal growth factor receptor (EGFR) intron 1 polymorphism and clinical outcome in pancreatic adenocarcinoma.
BACKGROUND
Epidermal growth factor receptor (EGFR) intron 1 has a polymorphic region of CA repeats that is believed to be associated with increased EGFR expression, tumor aggressiveness, and worse survival in cancer patients.


METHODS
A large population of pancreatic adenocarcinoma patients was investigated to evaluate this polymorphism as a potential prognostic marker of clinical outcome. Deoxyribonucleic acid obtained from 50 resected pancreatic adenocarcinomas and from 85 diagnostic endoscopic ultrasound-guided fine-needle aspiration procedures corresponding to patients with unresectable tumors was included. The correlation between CA repeat length and EGFR messenger ribonucleic acid levels was also examined.


RESULTS
Analysis of the 135 patients revealed no correlation between EGFR intron 1 CA repeat length and tumor stage. There was no difference in overall patient survival when stratified by allele length. A correlation between EGFR intron 1 length and EGFR transcript and protein levels could not be established.


CONCLUSIONS
The length of the EGFR intron 1 CA repeats does not correlate with levels of EGFR expression and cannot be used as marker of clinical prognosis in pancreatic cancer patients.
Frolov
Andrey
A
Department of Surgery, University of Alabama at Birmingham, USA. frolov@uab.edu
Liles
J Spencer
JS
Kossenkov
Andrew V
AV
Tzeng
Ching-Wei D
CW
Jhala
Nirag
N
Kulesza
Peter
P
Varadarajulu
Shyam
S
Eloubeidi
Mohamad
M
Heslin
Martin J
MJ
Arnoletti
J Pablo
JP
D000230:Adenocarcinoma / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D014408:Biomarkers, Tumor; D044963:Biopsy, Fine-Needle; D004273:DNA, Neoplasm / Q000032:analysis; D018773:Genes, erbB-1 / Q000235:genetics*; D006801:Humans; D015151:Immunoblotting; D007124:Immunoenzyme Techniques; D007438:Introns; D010190:Pancreatic Neoplasms / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D011110:Polymorphism, Genetic; D016016:Proportional Hazards Models; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015996:Survival Rate
D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm
Ann Surg. 2006 Jul;244(1):10-5
16794383
Pancreas. 2004 Jul;29(1):e1-8
15211117
J Pathol. 1992 Jan;166(1):7-12
1538276
Gene. 2006 Jan 17;366(1):2-16
16377102
Eur J Cancer. 2002 Nov;38(17):2258-64
12441262
Ann Surg Oncol. 2007 Jul;14(7):2150-8
17453292
Clin Cancer Res. 2003 Mar;9(3):1009-12
12631599
World J Gastroenterol. 2008 Feb 21;14(7):1053-9
18286687
Jpn J Cancer Res. 1987 Jan;78(1):54-62
3102439
Genes Chromosomes Cancer. 2008 Aug;47(8):657-64
18464244
Hum Genomics. 2009 Apr;3(3):236-45
19403458
Cancer Res. 2004 Dec 15;64(24):9139-43
15604284
Int J Biol Markers. 2000 Jan-Mar;15(1):105-10
10763151
Cancer Res. 2000 Feb 15;60(4):854-7
10706093
Mol Cancer Ther. 2003 Aug;2(8):699-709
12939459
Anticancer Res. 1993 May-Jun;13(3):565-9
8317885
Ann Oncol. 2005 Jun;16(6):934-41
15829495
J Biol Chem. 1999 May 7;274(19):13176-80
10224073
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385